Xiushi Biopharmaceuticals
Biosynthesis solutions for polypeptide drug development and manufacturing.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Series A | |
| Total Funding | 000k | ||
Related Content
Xiushi Biopharmaceuticals (Nantong) Co., Ltd. is a high-tech enterprise founded in 2020 specializing in the large-scale biosynthesis of polypeptide drugs. The company provides comprehensive services and products to global biotechnology and pharmaceutical companies, covering the entire lifecycle from drug research and clinical development to market launch. Its business model operates as a Contract Development and Manufacturing Organization (CDMO) and a Contract Manufacturing Organization (CMO), offering services such as Peptide Chemistry, Manufacturing, and Controls (CMC) development and manufacturing of peptide new chemical entities (NCEs) and generic drugs.
The company's core technology is a proprietary peptide biosynthesis platform that aims to be more efficient and environmentally friendly than traditional methods. This is supported by a team of scientists and engineers with extensive experience in synthetic biology and biomanufacturing. Xiushi Biopharma has a 5,000-square-meter R&D center and a 20,000-square-meter intelligent manufacturing base designed to meet Good Manufacturing Practice (GMP) standards. This allows for production at various scales, from grams to kilograms. Their product portfolio includes Semaglutide, Liraglutide, Tirzepatide, and Retatrutide. In May 2025, its Semaglutide, produced via a new bioprocess, successfully completed a U.S. Drug Master File (DMF) filing with the FDA.
The company's core technical team is composed of PhDs, university professors, and industry experts in synthetic biology, pharmaceuticals, and engineering. Xiushi Biopharma has received angel and Pre-A round funding from investors including Shicui Capital and Chuangjing Capital.
Keywords: polypeptide biosynthesis, CDMO services, CMO services, peptide drugs, drug development, biomanufacturing, synthetic biology, peptide CMC development, active pharmaceutical ingredient, Semaglutide, Liraglutide, Tirzepatide, generic drugs, GMP manufacturing, pharmaceutical services, drug discovery, clinical development, biopharmaceuticals, biotechnology